Chapter 55. Changes in the Airway With COPD. Manifestations of Severe COPD. Drugs Used to Treat Obstructive Pulmonary Disorders

Similar documents
Monocast Description Indications

RESPIRATORY PHARMACOLOGY - ASTHMA. Primary Exam Teaching - Westmead ED

Composition: Each tablet contain. Levocetirizine. Each 5ml contains. Montelukast. Pharmacokinetic properties:

Utibron Neohaler. (indacaterol, glycopyrrolate) New Product Slideshow

Composition Each ml of Ventol solution for inhalation contains 5 mg Salbutamol (as sulphate).

Atrovent Administration

History & Development

Respiratory Pharmacology. Manuel Otero Lopez Department of Anaesthetics and Intensive Care Hôpital Européen Georges Pompidou, Paris, France

Pharmaceutical form(s)/strength: Solution: 5 mg/ml Suspensions: 2.5 and 5 mg/ml P-RMS:

PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP

Medications Affecting The Respiratory System

Nursing Process Focus: Patients Receiving Salmeterol (Serevent)

Core Safety Profile. Pharmaceutical form(s)/strength: Sterile eye drops 1%, 2% Date of FAR:

Respiratory Pharmacology

Clinical Indications. Clinical Indications. RSPT 2317 Methylxanthines. RSPT 2317 Methylxanthines

COPD. Breathing Made Easier

Function of the Respiratory System. Exchange CO2 (on expiration) for O2 (on inspiration)

From the Text. Clinical Indications. Clinical Indications. Clinical Indications. Clinical Indications. RSPT 2317 Methylxanthines

Lungs SLO Practice (online) Page 1 of 5

BRICANYL INJECTION. terbutaline sulfate PRODUCT INFORMATION

IPRAVENT Respules/Respirator solution (Ipratropium bromide)

VACCINE-RELATED ALLERGIC REACTIONS

Each 5ml of Sinarest LP New Syrup contains: Phenylephrine

1 Chapter 13 Respiratory Emergencies 2 Respiratory Distress Patients often complain about. Shortness of breath Symptom of many different Cause can be

PRODUCT MONOGRAPH THEOLAIR. (theophylline anhydrous) Theolair Liquid 80 mg/15 ml. Bronchodilator. Date of Revision: February 13 th, 2013

Asthma Description. Asthma is a disease that affects the lungs defined as a chronic inflammatory disorder of the airways.

Drug Profiles Professional Responder

Respiratory Diseases and Disorders

Lecture Notes. Chapter 3: Asthma

Pharmacology of drugs used in bronchial asthma & COPD

NEW ZEALAND DATA SHEET

Chapter 7. Anticholinergic (Parasympatholytic) Bronchodilators. Mosby items and derived items 2008, 2002 by Mosby, Inc., an affiliate of Elsevier Inc.

PRODUCT INFORMATION. SUDAFED Sinus 12 Hour Relief Tablets

IPRAVENT Rotacaps (Ipratropium bromide)

3. Identify the importance in the prehospital setting for the administration of nebulized bronchodilator.

PRODUCT INFORMATION. Sudafed* Sinus + Anti-inflammatory Pain Relief Caplets

PRODUCT INFORMATION TILADE CFC-FREE

ASTHALIN Respules (Salbutamol sulphate)

SEROBID Inhaler (Salmeterol xinafoate)

Chronic inflammation of the airways Hyperactive bronchi Shortness of breath Tightness in chest Coughing Wheezing

Copyright, ICKE, Inc. All rights reserved. The Knowledge, Attitude, and Self-Efficacy. Asthma Questionnaire

Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup.

Angina pectoris due to coronary atherosclerosis : Atenolol is indicated for the long term management of patients with angina pectoris.

ASTHALIN Respirator Solution (Salbutamol sulphate)

VACCINE-RELATED ALLERGIC REACTIONS

Smoking and Nicotine Replacement Therapy (NRT) Lec:5

RESPIRATORY REHABILITATION

A COPD medication delivery device option: an overview of the NEOHALER

LACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION

Asthma Medications: Information for Children and Families. What You Need to Know about Medicines for Asthma

VENTOLIN RESPIRATOR SOLUTION

OXIS TURBUHALER 4.5 µg/dose and 9 µg/dose ASTRAZENECA

Urticaria Moderate Allergic Reaction Mild signs/symptoms with any of following: Dyspnea, possibly with wheezes Angioneurotic edema Systemic, not local

PRODUCT INFORMATION. Ammonium chloride is an expectorant that has an irritant effect on mucous membranes.

Pharmacology Drugs of Respiratory system. Drugs acting on respiratory system. Dr. Ahmad Al-Zohyri Lec. 11

Better Living with Obstructive Pulmonary Disease A Patient Guide

Basic mechanisms disturbing lung function and gas exchange

PRODUCT INFORMATION VENTOLIN DISKS

14 41 minutes Vd 218 t ½ 22 to 70 Clearance hours Protein Binding 71%, active metabolite 42% Bioavailability 3%

Medicine Dr. Kawa Lecture 4 - Treatment of asthma :

Using an Inhaler and Nebulizer

PBL RESPIRATORY SYSTEM DR. NATHEER OBAIDAT

Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs

Focus On: Reducing Risks and Coping with Chronic Diseases and Conditions

Antiallergics and drugs used in anaphylaxis

Air Flow Limitation. In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation.

PRODUCT INFORMATION INTAL CFC-FREE INHALER AND INTAL FORTE CFC-FREE INHALER

7.2 Part VI.2 Elements for a Public Summary

The usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials.

RESPIRATORY PHARMACOLOGY

Beta 1 Beta blockers A - Propranolol,

Glossary of Asthma Terms

Respiratory Emergencies. Chapter 11

Foundations of Pharmacology

Epiglottitis. Bronchitis. Bronchiolitis. Pneumonia. Croup syndrome. Miss. kamlah 2

Chapter 8. Learning Objectives. Learning Objectives 9/11/2012. Anaphylaxis. List symptoms of anaphylactic shock

Introduction to Emergency Medical Care 1

PARACOD Tablets (Paracetamol + Codeine phosphate)

*Monitor for significant side effects, especially symptoms of neurological or cardiovascular events.

Drugs used in obstetrics

Respiratory Anesthetic Emergencies in Oral and Maxillofacial Surgery. By: Lillian Han

The Respiratory System

Levocetirizine dihydrochloride

Respiratory System Anatomy Respiratory system: all the structures that contribute to

NEW ZEALAND DATA SHEET ACUPAN TM. 3. PHARMACEUTICAL FORM White, round, biconvex, film-coated tablets (7 mm diameter) engraved APN on one face.

Chapter 7. Principles of Pharmacology

MEDICATION GUIDE ANORO ELLIPTA

Summary of the risk management plan (RMP) for Duaklir Genuair (aclidinium / formoterol fumarate dihydrate)

Overview. The Respiratory System. Chapter 18. Respiratory Emergencies 9/11/2012

PRODUCT INFORMATION. (RS)-N,N-Dimethyl-2-[(2-methylphenyl)phenylmethoxy]ethanamine dihydrogen 2-hydroxypropane-1,2,3-tricarboxylate

PROSTIGMIN (neostigmine bromide)

1. NAME OF THE MEDICINAL PRODUCT. Vicks Sinex, 0.5 mg/ml, nasal spray solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Drugs acting on the respiratory tract

Phases of Respiration. Chapter 18: The Respiratory System. Structures of the Respiratory System. Structures of the Respiratory System

Care for patients with Neurological disorders

The Respiratory System

your breathing problems worsen quickly. you use your rescue inhaler, but it does not relieve your breathing problems.

Overview of COPD INTRODUCTION

Bronchial Asthma and COPD

Transcription:

Chapter 55 Drugs Used to Treat Obstructive Pulmonary Disorders Changes in the Airway With COPD Manifestations of Severe COPD Air is trapped in the lower respiratory tract The alveoli degenerate and fuse together The exchange of gases is greatly impaired

Preventive and Treatment Measures for COPD/asthma/emphysema Reduce environmental exposure to irritants Stop smoking Filter allergens from the air Avoid exposure to known irritants and allergens If these fail, we may need medication to Open the conducting airways through muscular bronchodilation Decrease the effects of inflammation on the airway lining Adult Respiratory Distress Syndrome (ARDS) Characteristics Progressive loss of lung compliance and increasing hypoxia due to a lack of surfactant and thus impaired opening of the alveoli. Causes Cardiovascular collapse, major burns, severe trauma, and rapid depressurization, prematurity Treatment Reversal of the underlying cause combined with ventilatory support Bronchodilators/Antiasthmatics Used to dilate the airways and thus facilitate respiration Used for asthma and bronchospasms associated with COPD. Given orally, so increased risk for systemic adverse effects If given via nebulizer, fewer risk for systemic adverse reactions.

Prototype Anticholinergic Bronchodilators Xanthines Action Direct effect on the smooth muscles of the respiratory tract, both in the bronchi and in the blood vessels Inhibit release of SRSA and histamine thus decreasing bronchial swelling Indication Symptomatic relief or prevention of bronchial asthma and for reversal of bronchospasm associated with COPD Also used to stimulate respirations in Cheyne-Stokes respiration and to treat apnea and bradycardia in premature infants Pharmacokinetics Narrow therapeutic margin, so no longer first line drugs Rapidly absorbed from the GI tract Metabolized in the liver and excreted in the urine Available in oral or parenteral form* Xanthines (cont.) Contraindications Caution with GI problems, coronary disease, respiratory dysfunction, renal or hepatic disease, alcoholism, and hyperthyroidism Adverse effects Related to theophylline levels in the blood (See table 55.3 on page 905) Therapeutic levels (10-20 mcg/ml) Increased levels cause GI upset, nausea, irritability, and tachycardia to seizure, brain damage, and even death Drug-to-drug interactions Many drugs interact with xanthines Nicotine increases xanthine metabolism*

Prototype Xanthines Screen for allergies or contraindications to its use Physical Assessment Teach pt to administer oral drugs with food or milk to relieve GI irritation Monitor the patient s response to the drug Provide comfort measures including rest periods, quiet environment, dietary control of caffeine, and headache therapy as needed Provide periodic follow-up including blood tests to monitor serum theophylline levels Provide thorough patient teaching Monitor the patient s response Monitor for adverse effects (CNS effects, cardiac arrythmias, GI upset, local irritation) Monitor for potential drug-drug interactions Evaluate the effectiveness of the teaching plan Monitor effectiveness of comfort measures and compliance with the regimen

Sympathomimetics Action Dilation of the bronchi with increased rate and depth of respiration. Beta 2 selective adrenergic agonists Systemic effects including increased BP, increased heart rate, vasoconstriction, and decreased renal and GI flow Indications Acute asthma attack Bronchospasm in acute or chronic asthma Prevention of exercise-induced asthma Pharmacokinetics Rapidly distributed after injection and transformed in the liver to metabolites that are excreted in the urine Only in pregnancy if benefits outweigh risks. Sympathomimetics (cont.) Contraindications Pregnancy and lactation Depend on the severity of the underlying condition and how systemic effects will effect these. Adverse effects Sympathomimetic stimulation CNS stimulation GI upset, cardiac arrhythmias, hypertension, bronchospasm, sweating, pallor, and flushing Drug-to-drug interactions General anesthetics* Screen for allergies or other contraindications for its use Physical assessment Instruct the patient on different responses to different drugs Advise patients to use the minimal amount needed for the shortest period to prevent adverse effects and accumulation of the drug Use 30-60 minutes prior to exercise Provide safety measures to prevent injury

Provide small, frequent meals and nutritional consultation if GI effects interfere with eating Teach the patient the proper use of the prescribed delivery system Provide thorough teaching Offer support and encourgement Monitor the patient s response to the drug Monitor for adverse effects Evaluate the effectiveness of the teaching plan Monitor the effectiveness of other measures to ease breathing Prototype Sympathomimetics Anticholinergic Bronchodilators Provide relief for patients who cannot tolerate the sympathetic effects of other drugs Action Anticholinergics block vagal effect therefore relaxing smooth muscle and leading to bronchodilation. Indication Maintenance treatment of bronchospasm associated with COPD and emphysema Pharmacokinetics Onset of action is 15 minutes when inhaled Peak in 1 to 2 hours; duration of action is 3 to 4 hours

Anticholinergic Bronchodilators (cont.) Cautions Any condition aggravated by the anticholinergic effects of the drug* Adverse effects Related to the anticholinergic effects of the drug Dizziness, headache, fatigue, nervousness, dry mouth, sore throat, palpitations, and urinary retention Screen for allergies or other contraindications to its use Physical Assessment Ensure adequate hydration and provide environmental controls such as a humidifier Encourage the pt to void before each dose to prevent urinary retention Provide safety measures to prevent injury Provide small, frequent meals and sugarless lozenges to relieve dry mouth and GI upset Review inhaler use; do not exceed 12 inhalations in 24 hours Advise the pt not to drive or use hazardous machinery Provide thorough patient teaching Offer support and encouragement Monitor the patient s response to the drug Monitor for adverse effects Evaluate the effectiveness of the teaching plan Monitor the effectiveness of other measures to ease breathing

Inhaled Steroids Action Decrease the inflammatory response in the airway and promote smooth muscle relaxation Indications Prevent and treat asthma Treat chronic steroid-dependent bronchial asthma Pharmacokinetics Well absorbed from the respiratory tract May take 2-3 weeks to reach effective levels Metabolized by natural systems, mostly within the liver, and excreted in the urine Inhaled Steroids (cont.) Contraindications Not used for emergency during an acute attack or status asthmaticus Pregnancy and lactation Used with caution in patients with active infection* Adverse effects Sore throat Hoarseness Coughing Dry mouth Pharyngeal and laryngeal fungal infections Prototype Inhaled Steroids

Screen for allergies and other contraindications to its use Physical Assessment Advise patient not to use the drug to treat an acute asthma attack or status asthmaticdus Taper systemic steroids carefully during the transfer to inhaled steroids Have the patient use decongestant drops before using the inhaled steroid Have the pt rinse the mouth after using the inhaler to decrease systemic absorption and decrease GI upset Monitor for any signs of respiratory infection Provide thorough patient teaching Offer support and encouragement Monitor the patient s response to the drug Monitor for adverse effects Evaluate the effectiveness of the teaching plan Monitor the effectiveness of other measures to ease breathing Leukotriene Receptor Antagonists Developed to act more specifically at the site of the problem associated with asthma Actions Selectively and competitively block or antagonize receptors for the production of leukotrienes thus blocking many of the signs and symptoms of asthma Indications Prophylaxis and chronic treatment of bronchial asthma in adults and in patients younger than 12 years of age Not for acute asthma attacks Pharmacokinetics Rapidly absorbed from the GI tract, extensively metabolized in the liver, and primarily excreted in the feces

Leukotriene Receptor Antagonists (cont.) Cautions Hepatic or renal impairment Pregnancy and lactation Adverse effects Headache, dizziness, myalgia, nausea, diarrhea, abdominal pain, elevated liver enzyme concentrations, vomiting, generalized pain, fever, and myalgia. Drug-to-drug interactions Propranolol, theophylline, terfenadine, and warfarin Calcium channel blockers, cyclosporine, and aspirin Prototype Leukotriene Receptor Antagonists Screen for allergies or other contraindications to its use Physical Assessment Teach pt to administer the drug on an empty stomach because food decreased the drugs availability Teach pts not to use for an acute asthma attack or bronchospasm Caution the patient to take the drug continuously and not to stop the medication during symptom free periods Provide appropriate safety measures to prevent injury Use pt to avoid OTC meds containing aspiring which interferes with the drugs effectiveness

Provide thorough patient teaching Offer support and encouragement Monitor patient s response to the drug Monitor for adverse effects Evaluate the effectiveness of the teaching plan Monitor the effectiveness of other measures to ease breathing Lung Surfactants Action Reduce the surface tension within the alveoli, allowing expansion and gas exchange Replace the surfactant that is missing in the lungs of neonates with RDS Indication Rescue treatment of infants who have developed RDS Prophylactic tx for those high risk for RDS Pharmacokinetics Begin to act immediately on instillation into the trachea Metabolized in the lungs Lung Surfactants (cont.) Contraindication Emergency drugs have no contraindication Adverse effects Patent ductus arteriosus Hypotension Intraventricular hemorrhage Pneumothorax Pulmonary air leak Hyperbilirubinemia Sepsis

Prototype Lung Surfactants Screen for time or birth and weight to determine appropriate dosage Physical Assessment Monitor the pt continuously during administration (life support measures may be needed) Ensure proper placement of the ET tube Ensure staff is knowledgable on med administration Suction the infant immediatley before administration, but not for 2 hours after administration to allow time for the drug to work Provide support and encouragement to parents Continue other supportive measures related to the patients prematurity Monitor the patient s response to the drug Monitor for adverse effects Evaluate the effectiveness of the teaching plan Support parents as appropriate Monitor the effectiveness of other measures to support breathing and stabilize the patient Evaluate the effectivenes of other support measures related to the immaturity of the infant

Mast Cell Stabilizers Action Prevent the release of inflammatory and bronchoconstricting substances when the mast cells are stimulated to release these substances because of irritation or the presence of an antigen Work at the cellular level to inhibit the release of histamine and SRSA Indications Treatment of chronic bronchial asthma Exercise-induced asthma Allergic rhinitis Pharmacokinetics Excreted during exhalations or in urine and feces Mast Cell Stabilizers (cont.) Contraindications Known allergy Cromolyn not during acute attack or for children under 2, Nedocromil not for under 12 y/o Pregnancy and lactation Mast Cell Stabilizers Adverse effects Cromolyn Swollen eyes, headache, dry mucosa, and nausea Nedocromil Headache, dizziness, fatigue, tearing, GI upset, and cough Drug-to-drug interactions Isoproterenol

Prototype Mast Cell Stabilizers Screen for allergies or other contraindications to its use Physical Assessment Teach proper use of delivery system Caution patients not to stop abruptly Caution patients to continue using the drug even during symptom free periods Administer oral drug 30 min before meals and at bedtime Initiate safety precautions to prevent injury Teach pts not to wear soft contact lenses as they can be stained or warped with Cromolyn eye drops Provide thorough patient teaching Offer support and encouragement Monitor patients response to the drug Monitor for adverse effects (drowsiness, dizziness, headache, GI upset, local irritation) Evaluate the effectiveness of the teaching plan Monitor the effectiveness of other measures to ease breathing

Use of Lower Respiratory Tract Agents Across the Lifespan